NLS Pharmaceutics ( (NLSP) ) has released a notification of late filing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NLS Pharmaceutics, a pharmaceutical company based in Zurich, Switzerland, has announced a delay in filing its Form 20-F (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the ongoing efforts to finalize a merger with Kadimastem Ltd. and the recent financial activities, including raising up to $3 million and securing a $25 million equity facility agreement. Despite these challenges, the company expects to file the report within the 15-day extension period allowed by regulations. There are no anticipated significant changes in financial results from the previous year. NLS Pharmaceutics is committed to completing the filing promptly, as stated by CEO Alexander Zwyer, who signed the notification.
More about NLS Pharmaceutics
YTD Price Performance: -32.48%
Average Trading Volume: 945,805
Technical Sentiment Signal: Buy
Current Market Cap: $3.64M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue